|
21 Nov 2023 |
Bioxodes closes €12 million in Series A funding round
|
|
21 Nov 2023 |
First Subject Enrolled in Phase 1 Study of MRX-5
|
|
21 Nov 2023 |
Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2201 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
|
|
21 Nov 2023 |
Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma
|
|
21 Nov 2023 |
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
|
|
21 Nov 2023 |
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
|
|
21 Nov 2023 |
Merck to Acquire Caraway Therapeutics, Inc.
|
|
20 Nov 2023 |
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
|
|
20 Nov 2023 |
Antibody Target, Technology & Pipeline Database: a cost-effective tool to stay tuned with latest information about therapeutic antibodies
|
|
20 Nov 2023 |
OCEANIC-AF study stopped early due to lack of efficacy
|
|
18 Nov 2023 |
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
|
|
18 Nov 2023 |
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
|
|
18 Nov 2023 |
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
|
|
17 Nov 2023 |
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
|
|
17 Nov 2023 |
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
|
|
17 Nov 2023 |
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
|
|
17 Nov 2023 |
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
|
|
17 Nov 2023 |
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
|
|
17 Nov 2023 |
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
|
|
17 Nov 2023 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
